Medscape

Cataract Surgery May Be Safer With Antibiotic Injections

Intracameral antibiotic injections decreased the risk for postoperative endophthalmitis after cataract surgery by 22-fold when compared with standard topical antibiotic drops in a new ecological ...
Healio

Be prepared for inflammation after cataract surgery

Please provide your email address to receive an email when new articles are posted on . Inflammation is a common but treatable complication of cataract surgery. While surgeons have tools to handle ...
Medscape

Study: Dropless Cataract Surgery Slashes Drug Costs With Comparable Effectiveness

A regimen that spares patients recovering from cataract surgery the burden of using antibacterial and anti-inflammatory eye drops several times a day for weeks and instead uses an injection to ...
Healio

Cataract surgery leads to ‘transient’ macular changes in AMD

Please provide your email address to receive an email when new articles are posted on . Central retinal thickness and macular volume increased at 2 months postop but returned to preop levels at 6 ...
Nasdaq

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...
Health on MSN

Can you get cataracts again after surgery?

Cataracts can't come back after surgery, but similar symptoms might appear. Secondary cataracts, caused by PCO, can develop after cataract surgery. Surgery effectively treats secondary cataracts and ...
Nasdaq

Regeneron Announces FDA Acceptance of Priority Review for EYLEA HD® Supplemental Application for Retinal Vein Occlusion Treatment

Regeneron Pharmaceuticals has announced the U.S. FDA's acceptance for Priority Review of the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg, which, if approved, ...
WTEN

First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years

TARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR ...